Trial Profile
A Randomized, Double-Blind, Placebo- And Active-Controlled Study Of The Pharmacokinetics, Pharmacodynamics And Safety Of Single Ascending Doses Of HM10660A (LAPS-INTERFERON ALPHA-2B) In Healthy Male Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Apr 2014
Price :
$35
*
At a glance
- Drugs Interferon alpha-2b (Primary) ; Peginterferon alfa-2a
- Indications Cancer; Hepatitis C
- Focus Adverse reactions
- Sponsors Hanmi Pharmaceutical
- 09 Jan 2012 New trial record